Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
How It Works 
News - Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI Summary - About
Coya Therapeutics, Inc. Common Stock(COYA)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Stock price based on last close Advisory Performance History (Simulated)
Upturn Advisory & Investor View for COYA
09/25/2026: COYA (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Coya Therapeutics is a clinical-stage biotechnology company focused on modulating regulatory T cells to treat neurodegenerative and autoimmune diseases. The firm's primary strength lies in its specialized platform and potential for therapeutic innovation in high-unmet-need areas like ALS. While the company offers a high-risk, high-reward growth story, it faces significant risks including clinical trial uncertainty, the need for continued funding, and intense competition from large pharmaceutical incumbents. It is suited for investors with a high risk tolerance who are willing to monitor binary clinical milestones. Investors should focus on future trial readouts and potential strategic partnerships as the primary catalysts for long-term value development.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Mixed fit | Coya represents a speculative growth opportunity based on clinical trial outcomes rather than current fundamental growth. |
| Momentum investor | Mixed fit | Momentum may occur around specific clinical milestone announcements, requiring active monitoring for upturn signals. |
| Value investor | Weak fit | The company lacks current earnings or assets that would typically support a value-based investment thesis. |
| Dividend investor | Weak fit | Coya does not pay a dividend and is not suitable for income-focused portfolios. |
| Low-risk investor | Weak fit | The high volatility and clinical risk associated with biotech development make this unsuitable for low-risk investors. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | High | Clinical-stage biotech stocks are subject to extreme swings based on trial results and regulatory updates. |
| Valuation risk | Medium / high | Valuations are speculative and sensitive to market appetite for biotech risk. |
| Competition risk (Immunology/Neuroscience) | High | Major pharmaceutical firms are aggressively targeting the same therapeutic areas with larger resources. |
| Business quality | Medium | The company is a research-focused organization; business quality will be proven by successful commercialization. |
| Dividend income | Low / none | There is no dividend policy, making it unsuitable for yield-seeking investors. |
| Execution risk | High | The company must successfully navigate complex clinical trials and the FDA approval process. |
Price Behavior
Rolling Over
The price momentum is slowing down and beginning to turn downward.
Choppy
The stock has experienced frequent reversals and pronounced short-term price swings.
Analysis of Past Performance
Type Stock | Historic Profit -18.43% | Avg. Invested days 29 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Advisory Rating  | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/25/2026 |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals
Financial Health Rating
Growth Momentum Score
Ownership
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue)
Economic Dimensions
Quantitative Style Profile
Style Classification
Quality Focused
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 119.17M USD | Price to earnings Ratio - | 1Y Target Price 15.21 |
Price to earnings Ratio - | 1Y Target Price 15.21 | ||
Volume (30-day avg) 130.2K shares | Beta 0.62 | 52 Weeks Range 3.71 - 7.75 | Updated Date 09/26/2026 |
52 Weeks Range 3.71 - 7.75 | Updated Date 09/26/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.07 |
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Clinical Development | Advancement of COYA 302 and COYA 301 therapeutic candidates. | Coya is an investment in successful drug development; revenue is currently not the primary focus. |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 75.52M | Price to Sales(TTM) 14.86 |
Enterprise Value 75.52M | Price to Sales(TTM) 14.86 | ||
Enterprise Value to Revenue 9.42 | Enterprise Value to EBITDA -6.21 | Shares Outstanding 23.46M | Shares Floating 17.54M |
Shares Outstanding 23.46M | Shares Floating 17.54M | ||
Percent Insiders 14.69 | Percent Institutions 33.26 |
Upturn AI Summary
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.
About Coya Therapeutics, Inc. Common Stock
Exchange NASDAQ | Headquarters Houston, TX, United States | ||
IPO Launch date 2022-12-29 | CEO & Director Dr. Arun Swaminathan Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 8 | Website https://www.coyatherapeutics.com |
Full time employees 8 | Website https://www.coyatherapeutics.com | ||
Coya Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of proprietary therapies to enhance the function of regulatory T cells (Tregs). Its candidate product pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy. The company develops COYA 302, a biologic combination for subcutaneous administration intended to enhance Treg function while depleting T effector function and activated macrophages in Phase 2 trial for use in the treatment of amyotrophic lateral sclerosis, as well as frontotemporal dementia, Alzheimer's disease (AD), and Parkinson's disease. In addition, its pre-clinical product candidates include COYA 301, a low-dose interleukin 2 product candidate to treat AD; COYA 303, an investigational biologic combination of COYA 301 and a glucagon-like-peptide-1 receptor agonist for the treatment of inflammatory diseases; COYA 201, an antigen directed Treg-derived exosome product candidate to treat neurodegenerative, autoimmune, and metabolic diseases; COYA 206, an antigen directed Treg-derived exosome product candidate; and COYA 101. It has a collaboration with Dr. Reddy's Laboratories SA for the development and commercialization of COYA 302, an investigational combination therapy for treatment of amyotrophic lateral sclerosis. Coya Therapeutics, Inc. was founded in 2020 and is headquartered in Houston, Texas.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.